Thursday, October 28, 2021
Home Health Trial Into Antioxidant for Parkinson's Disease Yields Disappointing Results

Trial Into Antioxidant for Parkinson’s Disease Yields Disappointing Results


By Cara MurezHealthDay Reporter

FRIDAY, Sept. 17, 2021 (HealthDay News) – Researchers hoped to show that the natural antioxidant urate could delay Parkinson’s disease progression, but a study completed at Massachusetts General Hospital dashed those expectations.

The trial enrolled nearly 300 individuals recently diagnosed with early Parkinson’s disease, which affects the body’s motor system. Symptoms such as tremors, stiff limbs and balance problems progress gradually, and there is no known cure.

The research team found no significant difference in the rate of disease progression for those given the metabolite inosine for two years compared to the placebo group.

Inosine raises levels of urate in the brain and blood. It has appeared neuroprotective in preclinical models.

The inosine did not prove beneficial, and those who received it also had an increased rate of kidney stones, according to the study.

“The convergence of epidemiological, biological and clinical data from past research made a compelling argument that elevating urate, the main antioxidant circulating in the blood, could protect against the oxidative damage thought to play a role in Parkinson’s disease,” said senior author Dr. Michael Schwarzschild, a neurologist at Mass General and a professor of neurology at Harvard Medical School.

“While our study did not rule out a protective effect of urate in Parkinson’s, it clearly showed that increasing urate did not slow disease progression based on clinical assessments and serial bran scan,” he added in a hospital news release.

Though it didn’t provide answers to disease progression, Schwarzschild said the study was successful in other ways.

“The findings were very helpful in providing a reality check that now allows the field to move on to other therapeutic approaches,” said Schwarzschild. “We also learned a lot in terms of clinical trials science for Parkinson’s, and ways to conduct future studies that will increase their chance of success.”

The findings were published Sept. 14 in the Journal of the American Medical Association.

More information

The Parkinson’s Foundation has more on Parkinson’s disease.

SOURCE: Massachusetts General Hospital-Harvard University, news release, Sept. 14, 2021



Source link

RELATED ARTICLES

Many Blood Cancer Patients Get Little Protection From COVID Vaccine

By Dennis Thompson HealthDay ReporterWEDNESDAY, Oct. 27, 2021 (HealthDay News) -- Anti-vaxxers felt their suspicions confirmed when former U.S. Secretary of State Colin...

Answers to Questions About the COVID Booster Recommendations

Oct. 27, 2021 -- Now that federal regulators have issued guidelines on booster doses for the COVID-19 vaccine, many people have many questions....

Why Kids Might Reject Sugar-Free Halloween Candy

Oct. 27, 2021 -- Trick-or-treaters may not be so easily tricked into loving sugar-free treats, thanks to taste buds hard-wired to seek calorie-containing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

How Rat Poison Helps Chemists Win Nobel Prizes

(Inside Science) —  Strychnine is a substance commonly deployed to keep rodents away from your kitchen.But a whole line of Nobel Prize winners...

Shanna Moakler on Travis Barker Replacing Her Tattoo: I’m Not Mad! I’m Not Petty!!

The newly engaged Travis Barker got a new tattoo of Kourtney Kardashian's lips. That sweet gesture towards his fiancee also served another purpose: erasing...

Recent Comments